The genetic landscape of ATC, including a higher frequency of TP53 mutation may directly impact local tumor immunity, resulting in a more robust immune response compared to other TC types with lower TP53 mutation frequencies [16,17,31,56,57,58]. This evidence concerns the gene TP53 and neoplasm.